Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure

Marina Morigi, Barbara Imberti, Carla Zoja, Daniela Corna, Susanna Tomasoni, Mauro Abbate, Daniela Rottoli, Stefania Angioletti, Ariela Benigni, Norberto Perico, Malcolm Alison, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Injury to a target organ can be sensed by bone marrow stem cells that migrate to the site of damage, undergo differentiation, and promote structural and functional repair. This remarkable stem cell capacity prompted an investigation of the potential of mesenchymal and hematopoietic stem cells to cure acute renal failure. The model of renal injury induced in mice by the anticancer agent cisplatin was chosen. Injection of mesenchymal stem cells of male bone marrow origin remarkably protected cisplatin-treated syngeneic female mice from renal function impairment and severe tubular injury. Y chromosome-containing cells localized in the context of the tubular epithelial lining and displayed binding sites for Lens culinaris lectin, indicating that mesenchymal stem cells engraft the damaged kidney and differentiate into tubular epithelial cells, thereby restoring renal structure and function. Mesenchymal stem cells markedly accelerated tubular proliferation in response to cisplatin-induced damage, as revealed by higher numbers of Ki-67-positive cells within the tubuli with respect to cisplatin-treated mice that were given saline. Hematopoietic stem cells failed to exert beneficial effects. These results offer a strong case for exploring the possibility that mesenchymal stem cells by virtue of their renotropic property and tubular regenerative potential may have a role in the treatment of acute renal failure in humans.

Original languageEnglish
Pages (from-to)1794-1804
Number of pages11
JournalJournal of the American Society of Nephrology
Volume15
Issue number7
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Mesenchymal Stromal Cells
Acute Kidney Injury
Cisplatin
Kidney
Hematopoietic Stem Cells
Wounds and Injuries
Stem Cells
Y Chromosome
Bone Marrow Cells
Antineoplastic Agents
Bone Marrow
Epithelial Cells
Binding Sites
Injections
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. / Morigi, Marina; Imberti, Barbara; Zoja, Carla; Corna, Daniela; Tomasoni, Susanna; Abbate, Mauro; Rottoli, Daniela; Angioletti, Stefania; Benigni, Ariela; Perico, Norberto; Alison, Malcolm; Remuzzi, Giuseppe.

In: Journal of the American Society of Nephrology, Vol. 15, No. 7, 07.2004, p. 1794-1804.

Research output: Contribution to journalArticle

@article{f2a42effb60c487f97061c2631874f35,
title = "Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure",
abstract = "Injury to a target organ can be sensed by bone marrow stem cells that migrate to the site of damage, undergo differentiation, and promote structural and functional repair. This remarkable stem cell capacity prompted an investigation of the potential of mesenchymal and hematopoietic stem cells to cure acute renal failure. The model of renal injury induced in mice by the anticancer agent cisplatin was chosen. Injection of mesenchymal stem cells of male bone marrow origin remarkably protected cisplatin-treated syngeneic female mice from renal function impairment and severe tubular injury. Y chromosome-containing cells localized in the context of the tubular epithelial lining and displayed binding sites for Lens culinaris lectin, indicating that mesenchymal stem cells engraft the damaged kidney and differentiate into tubular epithelial cells, thereby restoring renal structure and function. Mesenchymal stem cells markedly accelerated tubular proliferation in response to cisplatin-induced damage, as revealed by higher numbers of Ki-67-positive cells within the tubuli with respect to cisplatin-treated mice that were given saline. Hematopoietic stem cells failed to exert beneficial effects. These results offer a strong case for exploring the possibility that mesenchymal stem cells by virtue of their renotropic property and tubular regenerative potential may have a role in the treatment of acute renal failure in humans.",
author = "Marina Morigi and Barbara Imberti and Carla Zoja and Daniela Corna and Susanna Tomasoni and Mauro Abbate and Daniela Rottoli and Stefania Angioletti and Ariela Benigni and Norberto Perico and Malcolm Alison and Giuseppe Remuzzi",
year = "2004",
month = "7",
doi = "10.1097/01.ASN.0000128974.07460.34",
language = "English",
volume = "15",
pages = "1794--1804",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure

AU - Morigi, Marina

AU - Imberti, Barbara

AU - Zoja, Carla

AU - Corna, Daniela

AU - Tomasoni, Susanna

AU - Abbate, Mauro

AU - Rottoli, Daniela

AU - Angioletti, Stefania

AU - Benigni, Ariela

AU - Perico, Norberto

AU - Alison, Malcolm

AU - Remuzzi, Giuseppe

PY - 2004/7

Y1 - 2004/7

N2 - Injury to a target organ can be sensed by bone marrow stem cells that migrate to the site of damage, undergo differentiation, and promote structural and functional repair. This remarkable stem cell capacity prompted an investigation of the potential of mesenchymal and hematopoietic stem cells to cure acute renal failure. The model of renal injury induced in mice by the anticancer agent cisplatin was chosen. Injection of mesenchymal stem cells of male bone marrow origin remarkably protected cisplatin-treated syngeneic female mice from renal function impairment and severe tubular injury. Y chromosome-containing cells localized in the context of the tubular epithelial lining and displayed binding sites for Lens culinaris lectin, indicating that mesenchymal stem cells engraft the damaged kidney and differentiate into tubular epithelial cells, thereby restoring renal structure and function. Mesenchymal stem cells markedly accelerated tubular proliferation in response to cisplatin-induced damage, as revealed by higher numbers of Ki-67-positive cells within the tubuli with respect to cisplatin-treated mice that were given saline. Hematopoietic stem cells failed to exert beneficial effects. These results offer a strong case for exploring the possibility that mesenchymal stem cells by virtue of their renotropic property and tubular regenerative potential may have a role in the treatment of acute renal failure in humans.

AB - Injury to a target organ can be sensed by bone marrow stem cells that migrate to the site of damage, undergo differentiation, and promote structural and functional repair. This remarkable stem cell capacity prompted an investigation of the potential of mesenchymal and hematopoietic stem cells to cure acute renal failure. The model of renal injury induced in mice by the anticancer agent cisplatin was chosen. Injection of mesenchymal stem cells of male bone marrow origin remarkably protected cisplatin-treated syngeneic female mice from renal function impairment and severe tubular injury. Y chromosome-containing cells localized in the context of the tubular epithelial lining and displayed binding sites for Lens culinaris lectin, indicating that mesenchymal stem cells engraft the damaged kidney and differentiate into tubular epithelial cells, thereby restoring renal structure and function. Mesenchymal stem cells markedly accelerated tubular proliferation in response to cisplatin-induced damage, as revealed by higher numbers of Ki-67-positive cells within the tubuli with respect to cisplatin-treated mice that were given saline. Hematopoietic stem cells failed to exert beneficial effects. These results offer a strong case for exploring the possibility that mesenchymal stem cells by virtue of their renotropic property and tubular regenerative potential may have a role in the treatment of acute renal failure in humans.

UR - http://www.scopus.com/inward/record.url?scp=3042628474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042628474&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000128974.07460.34

DO - 10.1097/01.ASN.0000128974.07460.34

M3 - Article

C2 - 15213267

AN - SCOPUS:3042628474

VL - 15

SP - 1794

EP - 1804

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -